First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions
CholeraCholera Vaccine Toxicity
Interventions
BIOLOGICAL

PanChol

PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital Vaccine Unit, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER